Company / Operating Cash Flow
Monopar Therapeutics Operating Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$12.2M
FY2025
5-year range
-$12.2M / -$2.6M
FY2021-FY2025
Trend
-55.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has declined for 5 consecutive years, from -$1M in FY2017 to -$12M in FY2025.
Based on SEC 10-K filings.
-$12M in FY2025.
Declined from -$7M to -$12M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Monopar Therapeutics's operating cash flow has declined for 5 consecutive years.
- In FY2025, operating cash flow decreased 55.3% year-over-year.
- Peak operating cash flow was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$12.2M | -55.3% |
| FY2024 | -$7.9M | -8.7% |
| FY2023 | -$7.2M | -139.5% |
| FY2019 | -$3.0M | -14.9% |
| FY2018 | -$2.6M | -119.9% |
| FY2017 | -$1.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026